Gili Hart, PhD is a biotech executive with extensive experience in global drug development including strategic planning, management and execution of global programs ranging from pre-clinical through successful Phase 3 trials. Most recently Gili served as the CEO of SpliSense, a pre-clinical biotechnology company. Prior to SpliSense, Gili served as the CEO of Mitoconix Bio, a biopharmaceutical company focused on therapies for neurological disease. She also served as General Manager of OPKO Biologics and as Vice President of Pre-clinical and Clinical Pharmacology at PROLOR Biotech. Gili played a key role in the development of their long acting growth hormone and other products. PROLOR was acquired by OPKO, while the growth hormone program was partnered to Pfizer. Gili was a Research Fellow at Yale School of Medicine. She earned her PhD and MSc degrees from the Weizmann institute of Science and also holds a degree from Technion in Biotechnology Engineering.